LENVATINIB IN TREATMENT OF RADIOACTIVE IODINE-REFRACTORY WELL-DIFFERENTIATED THYROID CARCINOMA
https://doi.org/10.17650/2222-1468-2017-7-2-45-52
Abstract
Well-differentiated thyroid carcinoma (WDTC) comprises > 90 % of all cases of thyroid cancer. In 10–15 % of patients, distant metastases are detected which significantly worsen the prognosis. Radioactive iodine therapy remains the main type of treatment of this patient group, but for patients with so-called radioactive iodine-refractory WDTC the prognosis is very poor. After successful phase III studies, several drugs from the group of multikinase inhibitors are being used in clinical practice for treatment of radioactive iodine-refractory WDTC, for example lenvatinib. In this article, we present a group of patients with radioactive iodine-refractory WDTC who received lenvatinib therapy.
About the Authors
I. S. Romanov
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
23 Kashira Highway, Moscow 115478
A. M. Mudunov
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
23 Kashira Highway, Moscow 115478
P. A. Isaev
Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Russian Federation
Russian Federation
4 Korolev St., Obninsk 249036, Kaluga Region
Yu. M. Bychkov
Russian Scientific Center of Radiology
Russian Federation
Russian Federation
86 Profsouznaya St., Moscow 117997
M. B. Dolgushin
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
23 Kashira Highway, Moscow 115478
A. A. Odzharova
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
23 Kashira Highway, Moscow 115478
L. F. Romanova
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
23 Kashira Highway, Moscow 115478
References
1. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2015 г. (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена, филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 250 с.
2. American Cancer Society. Cancer Facts & Figures 2014. American Cancer Society. Available at http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.Accessed August 13, 2014.
3. Furuya-Kanamori L., Bell K.J.L., Clark J. et al. Prevalence of Differentiated Thyroid Cancer in Autopsy Studies Over Six Decades: A Meta-Analysis. Journal of Clinical Oncology 2016;34(30):3672–9.
4. Румянцев П.О., Ильин А.А., Румянцева У.В. и др. Рак щитовидной железы. Современные подходы к диагностике и лечению. М.: ГЭОТАРМедиа, 2009. [Rumyantsev P.O., Ilyin A. A., Rumjantseva U.V., etc. Cancer of the thyroid cancer. Modern approaches to diagnosis and treatment. Moscow: GEOTARMedia, 2009. (In Russia)].
5. O’Neill C.J., Oucharek J., Learoud D. et al. Standard and emerging therapies for metastatic differentiated thyroid cancer. The Oncologist 2010;15(2):146–56.
6. Sherman S.I. Thyroid carcinoma. Lancet 2003;361:501–11.
7. Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R. et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91:313–9.
8. Adam M.A., Thomas S., Hyslop T. et al. Exploring the Relationship Between Patient Age and Cancer-Specific Survival in Papillary Thyroid Cancer: Rethinking Current Staging Systems. Journal of Clinical Oncology 2016;34(36):4415–20.
9. Hoie J., Stenwig A.E., Kullmann G. et al. Distant metastases in papillary thyroid cancer: a review of 91 patients. Cancer 1988;61:1–6.
10. Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9.
11. Pittas A.G., Adler M., Fazzari M. et al. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 2000;10:261–8.
12. Jonklaas J., Sarlis N.J., Litofsky D. et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16(12):1229–42.
13. Casara D., Rubello D., Saladini G. et al. Different features of pulmonary metastases in differentiated thyroid cancer: Natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993;34:1626–31.
14. Hodak S.P., Carty S.E. Radioiodineresistant differentiated thyroid cancer: hope for the future. Oncology 2009;9:775–6.
15. Brose M., Nutting C.M., Sherman S.I. et al. Rationale and design of decision: a double-blind, randomized, placebocontrolled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 2011;11:349–70.
16. Румянцев П.О., Фомин Д.К., Румянцева У.В. Критерии резистентности высокодифференцированного рака щитовидной железы к терапии радиоактивным йодом. Опухоли головы и шеи 2014;3:4–9.
17. Резолюция Экспертного совета по вопросам таргетной терапии дифференцированного рака щитовидной железы, резистентного к терапии радиоактивным йодом. Опухоли головы и шеи 2014;3:10–1.
18. Schlumberger M., Brose M., Elisei R. et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2014;2(5):356–8.
19. Haugen B.R., Alexander E.K., Bible K.C. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26(1):1–133.
20. Shimaoka K., Schoenfeld D.A., DeWys W.D. et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56:2155–60.
21. Williams S.D., Birch R., Einhorn L.H. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: A Southeastern Cancer Study Group trial. Cancer Treat Rep 1986;70:405–7.
22. Nikiforova M.N., Nikiforov Y.E. Molecular genetics of thyroid cancer: Implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008;8:83–95.
23. Riesco-Eizaguirre G., Gutierrez-Martinez P., Garcia-Cabezas M.A. et al. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane. Endocr Relat Cancer 2006;13:257–69.
24. Durante C., Puxeddu E., Ferretti E. et al. RAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007;92:2840–3.
25. Romei C., Ciampi R., Faviana P. et al. BRAF V600E mutation, but not RET/ PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer 2008;15:511–20.
26. Liu Z., Hou P., Ji M. et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/ Akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008;93:3106–16.
27. Santarpia L., El-Naggar A.K., Cote G.J. et al. Phosphatidylinositol 3-kinase/Akt and Ras/Raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 2008;93:278–84.
28. Liu R., Xing M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer 2016;23(3):R143–R155.
29. Liu X., Bishop J., Shan Y. et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 2013;20(4):603–10.
30. Horn S., Figl A., Rachakonda P.S. et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013;339(6122):959–61.
31. Huang F.W., Hodis E., Xu M.J. et al. Highly recurrent TERT promoter mutations in human melanoma. Science2013;339(6122):957–9.
32. Liu R., Bishop J., Zhu G. et al. Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality. JAMA Oncology Published online September 1, 2016.
33. Castellone M.D., Carlomagno F., Salvatore G. et al. Receptor tyrosine kinase inhibitors in thyroid cancer. Best Pract Res Clin Endocrinol Metab 2008;22:1023–38.
34. Schlumberger M., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372:621–30.
35. Matsui J., Funahashi Y., Uenaka T. et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14(17):5459–65.
36. Grande E., Diez J.J., Zafon C. et al. Thyroid cancer: molecular aspects and new therapeutic strategies. J Thyroid Res 2012;2012:847108.
37. Stjepanovic N., Capdevila J. Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics 2014;8:129–39.
38. Gianoukakis A.G. et al. Response to lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC): Updated results from SELECT. J Clin Oncol 34;2016 (Suppl., abstr. 6089).
Review
For citations:
Romanov I.S., Mudunov A.M., Isaev P.A., Bychkov Yu.M., Dolgushin M.B., Odzharova A.A., Romanova L.F. LENVATINIB IN TREATMENT OF RADIOACTIVE IODINE-REFRACTORY WELL-DIFFERENTIATED THYROID CARCINOMA. Head and Neck Tumors (HNT). 2017;7(2):45-52. (In Russ.) https://doi.org/10.17650/2222-1468-2017-7-2-45-52
Views:
754
Email this article 